Learn More
OBJECTIVES Levetiracetam is a broad-spectrum antiepileptic drug (AED) which is currently licensed in the United States and the United Kingdom and Ireland for use as adjunctive treatment of focal-onset seizures and myoclonic seizures or generalized tonic-clonic seizures, occurring as part of generalized epilepsy syndromes. In the United Kingdom and Ireland,(More)
BACKGROUND Use of valproate in pregnancy, especially in doses over 1000mg a day, is known to be associated with a higher risk for major congenital malformations compared with other antiepileptic drugs. We sought to investigate whether the increased risk could be minimised by using controlled release or divided daily doses of valproate. METHODS The UK(More)
Epilepsy has special implications for women, especially during their childbearing years, and particularly when pregnancy is contemplated. Being aware of the relevant issues is therefore essential. For anyone with juvenile myoclonic epilepsy and other idiopathic generalised epilepsies, valproate is generally regarded as the gold standard treatment against(More)
Are We Failing Those With 'The Falling Sickness'? Time to modernise the approach to epilepsy care The epilepsies are a common, heterogeneous group of disorders linked by a tendency to recurrent seizures in affected individuals and which have no respect for age, gender, race or social status. A seizure is defined as an intermittent, stereotyped, disturbance(More)
Increased levetiracetam clearance in pregnancy: Is seizure frequency affected? Emerging data on the teratogenic potential of antiepileptic drugs (AEDs), in particular valproate, have resulted in a prescribing shift towards lamotrigine and levetiracetam in women of childbearing age with epilepsy. 1,2 Over the last 20 years prescription of lamotrigine to(More)
  • 1